Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    34.657,35
    +318,03 (+0,93%)
     

  • Dow Jones

    39.512,84
    +125,08 (+0,32%)
     

  • Nasdaq

    16.340,87
    -5,40 (-0,03%)
     

  • Nikkei 225

    38.229,11
    +155,13 (+0,41%)
     

  • Petrolio

    78,20
    -1,06 (-1,34%)
     

  • Bitcoin EUR

    56.479,02
    -67,34 (-0,12%)
     

  • CMC Crypto 200

    1.261,63
    -96,38 (-7,10%)
     

  • Oro

    2.366,90
    +26,60 (+1,14%)
     

  • EUR/USD

    1,0772
    -0,0012 (-0,11%)
     

  • S&P 500

    5.222,68
    +8,60 (+0,16%)
     

  • HANG SENG

    18.963,68
    +425,87 (+2,30%)
     

  • Euro Stoxx 50

    5.085,08
    +30,67 (+0,61%)
     

  • EUR/GBP

    0,8598
    -0,0010 (-0,11%)
     

  • EUR/CHF

    0,9760
    -0,0005 (-0,05%)
     

  • EUR/CAD

    1,4724
    -0,0020 (-0,14%)
     

Enovis to Host Third Quarter 2023 Results Conference Call on November 7th

Enovis Corporation
·1 minuto per la lettura
Enovis Corporation
Enovis Corporation

Wilmington, DE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its third quarter 2023 financial results on Tuesday, November 7, 2023 at 8:00 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the “Investors” section.

Conference call/Webcast Information

Investors can access a live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and ask to join the Enovis call. A link to a replay of the call will also be available on the Enovis website later that day.

ANNUNCIO PUBBLICITARIO

ABOUT ENOVIS

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.

Contact:

Kyle Rose
Vice President, Investor Relations
Enovis Corporation
+1-917-734-7450
investorrelations@enovis.com

***

Source: Enovis Corporation